Privi Speciality Chemicals Limited delivered a strong financial performance for the year ended March 31, 2026, with standalone net profit nearly doubling year-on-year and consolidated revenue from operations crossing Rs. 2,56,000 lakhs. The Board of Directors, at its meeting held on May 11, 2026, approved the audited standalone and consolidated financial results and recommended a final dividend for the financial year 2025-26. On a quarterly basis, consolidated revenue for Q4 stood at Rs. 72,151.78 lakhs versus Rs. 61,355.03 lakhs in the same period last year, with EBITDA expanding to Rs. 1.8B rupees from Rs. 1.33B rupees and EBITDA margin improving to 24.98% from 21.62% year-on-year.

Standalone Financial Performance

On a standalone basis, Privi Speciality Chemicals reported significant growth across key financial metrics for the year ended March 31, 2026. Revenue from operations rose to Rs. 2,45,553.47 lakhs from Rs. 2,03,834.26 lakhs in the previous year. Profit before tax surged to Rs. 47,898.62 lakhs from Rs. 25,386.91 lakhs, while net profit for the year nearly doubled to Rs. 35,744.19 lakhs from Rs. 18,930.25 lakhs. Basic and diluted earnings per share (EPS) for the full year stood at Rs. 91.50, compared to Rs. 48.46 in the previous year.

The following table summarises the standalone financial results:

For the quarter ended March 31, 2026, standalone revenue from operations was Rs. 66,034.73 lakhs, compared to Rs. 58,072.85 lakhs in the corresponding quarter of the previous year. Net profit for the quarter stood at Rs. 10,271.84 lakhs, against Rs. 6,612.29 lakhs in the same quarter last year. The quarter's basic and diluted EPS (not annualised) was Rs. 26.30.

Consolidated Financial Performance

On a consolidated basis, which includes Privi Biotechnologies Private Limited, Privi Speciality Chemicals USA Corporation, and Prigiv Specialties Private Limited, revenue from operations for the year ended March 31, 2026 grew to Rs. 2,56,368.55 lakhs from Rs. 2,10,119.09 lakhs. Consolidated profit before tax rose to Rs. 43,970.20 lakhs from Rs. 25,452.28 lakhs. Consolidated net profit for the year was Rs. 31,672.10 lakhs, compared to Rs. 18,475.03 lakhs in the previous year. Net profit attributable to owners of the Holding Company was Rs. 32,753.73 lakhs.

*not annualised

For the quarter ended March 31, 2026, consolidated performance reflected robust year-on-year improvement across key metrics. The following table presents the Q4 consolidated highlights:

Balance Sheet and Cash Flow Highlights

As at March 31, 2026, standalone total assets stood at Rs. 2,88,309.87 lakhs, compared to Rs. 2,47,343.61 lakhs as at March 31, 2025. Total standalone equity increased to Rs. 1,43,764.15 lakhs from Rs. 1,10,119.27 lakhs. On a consolidated basis, total assets were Rs. 3,16,982.01 lakhs as at March 31, 2026, against Rs. 2,79,050.62 lakhs in the prior year. Standalone net cash generated from operating activities for the year was Rs. 55,927.97 lakhs, compared to Rs. 30,404.57 lakhs in the previous year. The consolidated net cash generated from operating activities was Rs. 55,008.69 lakhs, against Rs. 28,111.04 lakhs in the previous year. The company operates within a single segment — Aroma Chemical — as per Ind AS 108.

Dividend, AGM, and Corporate Developments

The Board has recommended a final dividend of Rs. 10/- (100%) per equity share of face value Rs. 10/- each for the financial year 2025-26, aggregating to Rs. 3,906.27 lakhs, subject to shareholder approval at the 41st Annual General Meeting. Key corporate calendar dates are as follows:

The Board also approved the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi (DIN: 00356218) as Executive Director (Whole-time Director) for a period of 3 years with effect from August 13, 2026 to August 12, 2029, subject to shareholder approval. Mr. Doppalapudi has been associated with the Privi group since 1982 and oversees Operations, Research & Development, Personnel and raw material sourcing. Additionally, M/s. Aneja Associates, Chartered Accountants, were re-appointed as Internal Auditor, and M/s. Kishore Bhatia & Associates (Firm Registration Number 00294 & ICMA M. No. 8241) were re-appointed as Cost Auditors, both for the Financial Year 2026-27. The statutory auditors, M/s. BSR & Co. LLP, have issued an unmodified audit opinion on both the standalone and consolidated financial results for the year ended March 31, 2026.

Privi Speciality Chemicals Limited has received observation letters with 'no objection' from both BSE Limited and the National Stock Exchange of India Limited, marking a significant regulatory milestone in its proposed scheme of amalgamation. The BSE observation letter is dated May 06, 2026, while the NSE observation letter was dated May 05, 2026. Both disclosures were made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on May 06, 2026. The observation letters are also being hosted on the company's website at https://privi.com/investor-relations/scheme-of-amalgamation-2025 .

Scheme of Amalgamation: Key Details

The proposed scheme involves the amalgamation of two transferor companies into Privi Speciality Chemicals Limited, which serves as the Transferee Company. The structure of the scheme is outlined below:

Background and Regulatory Progress

The Board of Directors of Privi Speciality Chemicals Limited had approved the proposed scheme of amalgamation between PSCL, PFSPL, and PBPL, along with their respective shareholders and creditors, as communicated through an earlier intimation dated December 19, 2025. The approval was granted subject to the receipt of requisite regulatory and statutory approvals. With observation letters now received from both NSE and BSE, the company has cleared two significant regulatory hurdles in the amalgamation process.

Pending Approvals

While both stock exchanges have issued their 'no objection' observation letters, the scheme remains subject to all other applicable regulatory and statutory approvals as required.

The intimation was signed by Ashwini Saumil Shah, Company Secretary and Compliance Officer of Privi Speciality Chemicals Limited, on May 06, 2026.